Please share what your organisation and Boehringer Ingelheim will Co-Create together
To empower patients we will co-create a digital therapeutic solution focused in COPD and using as a testing market Canada the English/French speaking population and the non-English/French speaking population.
During many weeks we have been working closely with some BI stakeholders, investigating reports generated by BI and also talking with many international experts, that we have relationship, to co create an initiative that aim to change the role of patients in the health system, empowering them through education.
This initiative is supported by a very powerful technology and a set of educative programs in many languages and cultural aspects. To educate patients we will use education based in clinical evidence and this education will be delivered by mobile phones and using audiovisual animations.
This co creation initiative will be a status quo changer and will impulse a social revolution that is happening: the patient revolution where patient is in the center of the stage and make better decisions taking control of his own health.
Please specify what your Co-Creation will result in:
a new product, a new distribution channel, a new market/customer group, other (please explain below).
If you selected "other" above, please explain:
Helping non-English/French speaking COPD patients in Canada truly understand their condition and impacting the whole society.
Please provide a 1-2 sentence summary of your Co-Creation idea
BI in partnership with ViperMed will develop a mobile patient education tool that can be accessible to patients at the time of diagnosis and in their language of choice.
Together we will co-create a digital patient education solution for COPD patients aimed in the short term to:
• help patients understand the disease.
• maximize the adherence to treatments by understanding their medication(s) and
• reinforce the self-care behavior related to their chronic disease.
In the mid/long term to:
• reduce the healthcare costs,
• decrease unnecessary revisits to primary care hospitals and clinics.
Collaborative discussions with Noora Health has taken place and ViperMed educative programs that are relevant to educating patient and their families in rural India will be taken and used by Noora Health to bring awareness to these communities.
How does this project link to the core mission of your organisation?
ViperMed is a patient education company, that specializes in projects that focuses to empower patients through education. Currently, we are working with 11 clients educating more than 4500 patients. In fact, ViperMed is working with The Ministry of Health of Uruguay with smoking cessation programs as well. So, developing a patient education tool for COPD aligns directly with our company’s mandate as well as active involvement on WHO public policy initiatives involving digital therapeutic program on smoking cessation.
Beyond social impact, how does this project link to Boehringer Ingelheim’s core business?
COPD is one of BI’s core therapeutic focuses worldwide. BI has a strong foothold on bronchodilator treatments and with the help of ViperMed, BI can be actively engaged on patient-centric initiatives such as this one, which is a patient education solution that would ultimately lead to patient behaviour changes and changes to patient-doctor interactions. By collaborating with ViperMed, BI will empower their patients by helping them to better understand their health condition, and also increase patient adherence to the treatments prescribed by doctors. In Canada, the bronchodilator business is about 1.2 billion dollars, of which COPD roughly is 50% of this and maintaining competiveness in this market requires BI to put more emphasis on patient needs and patient education is a huge component of this.
What are the specific inputs and actions that each side will contribute to this Co-Creation idea based on each of your unique competencies and experiences?
○ My organization will contribute:
-Expertise in the development of the mobile/PC/Tablet technology to implement the patient education program following an understanding of patient needs.
-Technological platforms that can enable telemedicine and patient monitoring in order to address patient adherence needs.
-Expertise in the development of curated audio-visual patient educative contents from top knowledge generators in the world (BMJ as sample).
-Expertise in the implementation and measurement of exponential and social impact projects.
○ Boehringer Ingelheim will contribute:
-Medical knowledge (both internally and via affiliations with external members of the medical community) worldwide
-Capital means to roll out projects that align directly with BI corporate strategy
-Patient- focused initiatives are high on BI's company mandate both in Canada and globally
-A global channel to make our initiative a reality.
Please describe the potential revenue model for this Co-Creation idea.
With this initiative we will be approaching COPD and each hospital will have the chance to educate their patients about how to manage the pathology. We will generate commercial relationships with each hospital that can be a ViperMed client adopting one of our 180 different educative programs with their population in the same way they will be doing with COPD. With each client we can make specific proposals based in the needs that they have and using an upselling strategy of our commercial team and strategy, offer them more ViperMed products that may be complementary with the COPD educative program.
What possible risks or challenges do you foresee?
Empowering patient through knowledge can be negatively viewed by conservative medical professionals as they may fear that patients may not have the capacity to fully understand their health and therefore, more information could result in a negative impact. There is an increasing trend for patient ownership of their health and for family members to take on caregiver roles to assist in the overall healthcare. By taking this into consideration, ViperMed’s expertise and experience in patient education, will be of great benefit to mitigate these risks and offer solutions that have been shown to be effective.
The implementation of this initiative has risks in terms of personal data protection laws, there are more advanced countries but many countries have not adapted a solution to support the security protocols.
Finally gathering evidence about the therapeutic impact is a challenge that we will need to approach in order to empower the replication of the initiative worldwide.
Is there anything else you would like to share about your Co-Creation idea?
Since last 2 years many pharmaceutical companies like Novartis, GlaxoSmithKline and Pfizer approached us concerning that they need to educate the patients. In 2013, we participated in an initiative from Novartis providing education to patients that had received a liver transplant. We know that patient education is an excellent complementary to the treatment, and many laboratories showed us that this is a must have.
90% of patients search education over Internet so providing a trusted education in a proactive way will not only increase the relationship with customers but also increase the patient compliance and revenues.
Since ViperMed born we used the prototype as a core element and in this case we decided to implement a prototype:
- The attachment: FutureOfMedication.jpg
-The multi language Video: https://vimeo.com/138415323
-A COPD educative video sample: https://vimeo.com/149711610
If you selected "other" above, please explain:
BI can provide us a very valious market information that may help us to focus our growing efforts.
Besides Boehringer Ingelheim, what other types of partners might be valuable to carrying out your Co-Creation idea, and why?
We will generate partnerships for the worldwide approach and also in each country that we implement the initiative. In each country will partner with medical associations to spread out the solution and to make it available to all the doctors, also is important to partner with the Ministry of Health of each country to align our initiative with their public policies with. At a higher level we will develop partnerships with trusted institutions that provide the education contents (like BMJ our partner) and also to have the explicit interest of the World Health Organization through their “be Mobile” initiative.